Needham reiterated coverage on Surmodics with a new price target
$SRDX
Medical/Dental Instruments
Health Care
Needham reiterated coverage of Surmodics with a rating of Buy and set a new price target of $76.00 from $68.00 previously
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 3/7/2025 | $43.00 | Hold → Buy | Lake Street |
| 6/13/2023 | $36.00 | Hold → Buy | Needham |
| 2/13/2023 | Buy → Hold | Needham | |
| 2/4/2022 | $70.00 → $58.00 | Buy | Needham |
| 11/10/2021 | $76.00 → $70.00 | Buy | Needham |
| 9/8/2021 | $68.00 → $76.00 | Buy | Needham |
Surmodics, Inc. (NASDAQ:SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today reported financial results for its second quarter ended March 31, 2025, and introduced its financial guidance for the fiscal year ending September 30, 2025. Second Quarter Fiscal 2025 Financial Summary Total Revenue of $28.1 million, a decrease of 12% year-over-year Total Revenue excluding SurVeil™ drug-coated balloon ("DCB") license fee revenue(1) of $27.8 million, a decrease of 10% year-over-year GAAP loss of $(5.2) million, compared to net income of $0.2 million in the prior-year period Adjusted EBITDA(2) of $1.9 million, compared to $4.8 mil
Surmodics, Inc. (NASDAQ:SRDX), a leading provider of medical device and in vitro diagnostic technologies to the health care industry, today announced that second quarter of fiscal year 2025 financial results will be released before the market opens on Wednesday, April 30. Given the pending acquisition by GTCR, Surmodics will not be hosting a live webcast and conference call to discuss the second quarter of fiscal 2025 financial results and accomplishments. About Surmodics, Inc. Surmodics is a leading provider of performance coating technologies for intravascular medical devices and chemical and biological components for in vitro diagnostic immunoassay tests and microarrays. Surmodics als
European Journal of Vascular and Endovascular Surgery Publishes Results Showing Comparable Safety and Efficacy of SurVeil™ DCB Despite IN.PACT™ Admiral™ DCB having 75% Higher Paclitaxel Dose. Surmodics, Inc. (NASDAQ:SRDX), a leading provider of medical device and in vitro diagnostic technologies to the health care industry, today announced the publication of the TRANSCEND clinical trial, a global randomized study demonstrating the SurVeil™ drug-coated balloon (DCB) is non-inferior to the IN.PACT™ Admiral™ DCB for safety and efficacy in patients with femoropopliteal arterial disease while using a substantially lower drug dose. The findings were published in the March 2025 edition of the Eur
4 - SURMODICS INC (0000924717) (Issuer)
4 - SURMODICS INC (0000924717) (Issuer)
4 - SURMODICS INC (0000924717) (Issuer)
Surmodics, Inc. (NASDAQ:SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today reported financial results for its second quarter ended March 31, 2025, and introduced its financial guidance for the fiscal year ending September 30, 2025. Second Quarter Fiscal 2025 Financial Summary Total Revenue of $28.1 million, a decrease of 12% year-over-year Total Revenue excluding SurVeil™ drug-coated balloon ("DCB") license fee revenue(1) of $27.8 million, a decrease of 10% year-over-year GAAP loss of $(5.2) million, compared to net income of $0.2 million in the prior-year period Adjusted EBITDA(2) of $1.9 million, compared to $4.8 mil
Surmodics, Inc. (NASDAQ:SRDX), a leading provider of medical device and in vitro diagnostic technologies to the health care industry, today announced that second quarter of fiscal year 2025 financial results will be released before the market opens on Wednesday, April 30. Given the pending acquisition by GTCR, Surmodics will not be hosting a live webcast and conference call to discuss the second quarter of fiscal 2025 financial results and accomplishments. About Surmodics, Inc. Surmodics is a leading provider of performance coating technologies for intravascular medical devices and chemical and biological components for in vitro diagnostic immunoassay tests and microarrays. Surmodics als
Surmodics, Inc. (NASDAQ:SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today reported financial results for its first quarter ended December 31, 2024. First Quarter Fiscal 2025 Financial Summary Total Revenue of $29.9 million, a decrease of 2% year-over-year Total Revenue excluding SurVeil™ drug-coated balloon ("DCB") license fee revenue(1) of $28.7 million, a decrease of 3% year-over-year GAAP net loss of $(3.7) million, compared to $(0.8) million in the prior-year period Adjusted EBITDA(2) of $3.6 million, compared to $3.9 million in the prior-year period First Quarter and Recent Business Highlights On May 2
8-K - SURMODICS INC (0000924717) (Filer)
SCHEDULE 13G/A - SURMODICS INC (0000924717) (Subject)
SCHEDULE 13D - SURMODICS INC (0000924717) (Subject)
Lake Street upgraded Surmodics from Hold to Buy and set a new price target of $43.00
Needham upgraded Surmodics from Hold to Buy and set a new price target of $36.00
Needham downgraded Surmodics from Buy to Hold
SC 13G/A - SURMODICS INC (0000924717) (Subject)
SC 13G/A - SURMODICS INC (0000924717) (Subject)
SC 13G/A - SURMODICS INC (0000924717) (Subject)
KORU Medical Systems, Inc. (NASDAQ:KRMD) ("KORU Medical" or the "Company"), a leading medical technology company focused on the development, manufacturing, and commercialization of innovative and easy-to-use specialty subcutaneous infusion solutions that improve quality of life for patients, today announced the appointment of Andrew D. C. LaFrence as its Chief Financial Officer, effective July 10, 2023. Andy LaFrence joins KORU Medical bringing over 39 years of finance and accounting experience, including a track record of successfully executing and influencing growth-oriented business and M&A strategies, scaling businesses, developing and managing a global team of finance and accounting